Abstract
In lung cancer, frequent loss of one allele of chromosome 3p is seen in both small cell lung cancer and non-small cell lung cancer (NSCLC), providing evidence of tumor suppressor genes (TSGs) in this chromosomal region. The mechanism of Fus1 tumor suppressor activity is unknown. We have found that a Fus1 peptide inhibits the Abl tyrosine kinase in vitro (IC50 35 μ M). The inhibitory Fus1 sequence was derived from a region that was deleted in a mutant FUS1 gene (FUS1 (1–80)) detected in some lung cancer cell lines. Importantly, a stearic acid-modified form of this peptide was required for the inhibition, but stearic acid alone was not inhibitory. Two NSCLC cell lines, which lack expression of wild-type Fus1, contain activated c-Abl. Forced expression of an inducible FUS1 cDNA in H1299 NSCLC cells decreased levels of activated c-Abl and inhibited its tyrosine kinase activity. Similarly, treatment of c-Abl immune complexes with the inhibitory Fus1 peptide also reduced the level of c-Abl in these immune complexes. The size and number of colonies of the NSCLC cell line, H1299, in soft agar was strongly inhibited by the Abl kinase inhibitor imatinib mesylate. Co-expression of FUS1 and c-ABL in COS1 cells blocked activation of c-Abl tyrosine kinase. In contrast, co-expression of mutant FUS1 (1–80) with c-ABL had little inhibitory activity against c-Abl. These findings provide strong evidence that c-Abl is a possible target in NSCLC patients that have reduced expression of Fus1 in their tumor cells.
Similar content being viewed by others
References
Brasher B, Van Etten R . (2000). c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275: 631–637.
Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker B et al. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100–104.
Das A, Sato M, Story M, Peyton M, Graves R, Redpath S et al. (2006). Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66: 9601–9608.
Dowell J, Minna J . (2005). Chasing mutations in the epidermal growth factor in lung cancer. N Eng J Med 352: 830–832.
Feller SM, Ren R, Hanafusa H, Baltimore D . (1994). SH2 and SH3 domains as molecular adhesives: the interactions of Crk and Abl. Trends Biochem Sci 19: 453–458.
Girard L, Zochbauer-Muller S, Virmani A, Gazdar A, Minna J . (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60: 4894–4906.
Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuryian J et al. (2003). A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112: 845–857.
Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch C et al. (2004). Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11: 733–739 1–7.
Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C et al. (2002). Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62: 2715–2720.
Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y et al. (2001). Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20: 6258–6262.
Ling X, Ma G, Sun T, Liu J, Arlinghaus R . (2003). Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. Cancer Res 63: 298–303.
Liu J, Wu Y, Arlinghaus R . (1996). Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56: 5120–5124.
Liu J, Campbell M, Guo J, Lu D, Xian Y, Andersson B et al. (1993). BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene 8: 101–109.
Miller C, Chen G, Gharib T, Wang H, Thomas D, Misek D et al. (2003). Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22: 7950–7957.
Pendergast A . (2002). The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res:, 51–100.
Plattner R, Kadlec L, DeMali K, Kazlauskas A, Pendergast A . (1999). c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13: 2400–2411.
Pluk H, Dorey K, Superti-Furga G . (2002). Autoinhibition of c-Abl. Cell 108: 247–259.
Samanta A, Lin H, Wang Y, Kantarjian H, Arlinghaus R . (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Can Res 66: 6468–6472.
Srinivasan D, Plattner R . (2006). Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66: 5648–5655.
Taagepera S, McDonald D, Loeb J, Whitaker L, McElroy A, Wang J et al. (1998). Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci 95: 7457–7462.
Tanos B, Pendergast AM . (2006). Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 28: 32714–32723.
Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson E et al. (2004). Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 64: 2969–2976.
US Cancer Statistics Working Group (2004). US Cancer Statistics: 2001 Incidence and Mortality. US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute: Atlanta, GA.
Wang J . (2000). Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643–5650.
Wen S, Van Etten R . (1997). The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11: 2456–2467.
Woodring P, Hunter T, Wang J . (2003). Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 116 (PT 13): 2613–2626.
Zabarovsky E, Lerman M, Minna J . (2002). Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915–6935.
Zhang P, Gao W, Turner S, Ducatman B . (2003). Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2: 1.
Zhang M, Zhang X, Bai C, Chen J, Wei M . (2004). Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 25: 61–67.
Acknowledgements
This work was funded in part by the Lung SPORE Grant P50CA70907. We thank Professor Ray Meyn for supplying the CCD16 normal lung fibroblasts.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, J., Sun, T., Ji, L. et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26, 6989–6996 (2007). https://doi.org/10.1038/sj.onc.1210500
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210500
- Springer Nature Limited
Keywords
This article is cited by
-
MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Cell Communication and Signaling (2022)
-
Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications
Cancer Gene Therapy (2022)
-
A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies
BMC Complementary Medicine and Therapies (2020)
-
Enabling Tumor Growth and Progression: Recent Progress in Unraveling the Functions of ABL Kinases in Solid Tumor Cells
Current Pharmacology Reports (2018)
-
Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway
Scientific Reports (2014)